Your browser doesn't support javascript.
loading
Machine learning in primary biliary cholangitis: A novel approach for risk stratification.
Gerussi, Alessio; Verda, Damiano; Bernasconi, Davide Paolo; Carbone, Marco; Komori, Atsumasa; Abe, Masanori; Inao, Mie; Namisaki, Tadashi; Mochida, Satoshi; Yoshiji, Hitoshi; Hirschfield, Gideon; Lindor, Keith; Pares, Albert; Corpechot, Christophe; Cazzagon, Nora; Floreani, Annarosa; Marzioni, Marco; Alvaro, Domenico; Vespasiani-Gentilucci, Umberto; Cristoferi, Laura; Valsecchi, Maria Grazia; Muselli, Marco; Hansen, Bettina E; Tanaka, Atsushi; Invernizzi, Pietro.
Affiliation
  • Gerussi A; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Verda D; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.
  • Bernasconi DP; Rulex Inc, Newton, Massachusetts, USA.
  • Carbone M; Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Komori A; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Abe M; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.
  • Inao M; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.
  • Namisaki T; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Mochida S; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Yoshiji H; Department of Gastroenterology, Nara Medical University, Nara, Japan.
  • Hirschfield G; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Lindor K; Department of Gastroenterology, Nara Medical University, Nara, Japan.
  • Pares A; Toronto Centre for Liver Disease, Toronto Western & General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Corpechot C; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Cazzagon N; Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, United States.
  • Floreani A; Arizona State University, Phoenix, Arizona, United States.
  • Marzioni M; Liver Unit, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Alvaro D; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hospital Clinic de Barcelona, Barcelona, Spain.
  • Vespasiani-Gentilucci U; Centre de Référence des Maladies Inflammatoires des Voies Biliaires et des Hépatites auto-immunes, Hôpital Saint- Antoine, APHP-Sorbonne Université, Paris, France.
  • Cristoferi L; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Saint-Antoine, Paris, France.
  • Valsecchi MG; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Muselli M; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Azienda Ospedale - Università Padova, Padova, Italy.
  • Hansen BE; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Tanaka A; Scientific Institute for Research, Hospitalization and Healthcare, Verona, Italy.
  • Invernizzi P; Division of Gastroenterology and Hepatology, Ospedali Riuniti University Hospital, Ancona, Italy.
Liver Int ; 42(3): 615-627, 2022 03.
Article in En | MEDLINE | ID: mdl-34951722
BACKGROUND & AIMS: Machine learning (ML) provides new approaches for prognostication through the identification of novel subgroups of patients. We explored whether ML could support disease sub-phenotyping and risk stratification in primary biliary cholangitis (PBC). METHODS: ML was applied to an international dataset of PBC patients. The dataset was split into a derivation cohort (training set) and a validation cohort (validation set), and key clinical features were analysed. The outcome was a composite of liver-related death or liver transplantation. ML and standard survival analysis were performed. RESULTS: The training set was composed of 11,819 subjects, while the validation set was composed of 1,069 subjects. ML identified four clusters of patients characterized by different phenotypes and long-term prognosis. Cluster 1 (n = 3566) included patients with excellent prognosis, whereas Cluster 2 (n = 3966) consisted of individuals at worse prognosis differing from Cluster 1 only for albumin levels around the limit of normal. Cluster 3 (n = 2379) included young patients with florid cholestasis and Cluster 4 (n = 1908) comprised advanced cases. Further sub-analyses on the dynamics of albumin within the normal range revealed that ursodeoxycholic acid-induced increase of albumin >1.2 x lower limit of normal (LLN) is associated with improved transplant-free survival. CONCLUSIONS: Unsupervised ML identified four novel groups of PBC patients with different phenotypes and prognosis and highlighted subtle variations of albumin within the normal range. Therapy-induced increase of albumin >1.2 x LLN should be considered a treatment goal.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Cholangitis / Liver Cirrhosis, Biliary Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2022 Type: Article Affiliation country: Italy

Full text: 1 Database: MEDLINE Main subject: Cholangitis / Liver Cirrhosis, Biliary Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2022 Type: Article Affiliation country: Italy